title: Expression of COX-2 and VEGF-C in cholangiocarcinomas at different clinical and pathological stages.
abstract: The aim of this study was to investigate the expression and clinical significance of cyclooxygenase 2 (COX-2) and vascular en-dothelial growth factor C (VEGF-C) in cholangiocarcinomas at differ-ent clinical and pathological stages. Eighty cholangiocarcinoma sam-ples of patients treated with surgery between January 2012 and January 2014 were collected. Immunohistochemistry was used to detect COX-2 and VEGF-C expression at different clinical and pathological stages. ELISA, real-time PCR, invasive chambers, and MTT assay were ap-plied in cultured cholangiocarcinoma cells treated with a COX-2 inhib-itor. Expression of COX-2 and VEGF-C correlated positively with the clinical TNM stage but did not correlate with the differentiation status. Inhibition of COX-2 activity reduced VEGF-C mRNA expression and secretion in cholangiocarcinoma cells and decreased their migration but not proliferation. Because of its ability to inhibit invasion, COX-2 could be a new target for treatment of cholangiocarcinoma.
authors.affiliation: Biliary Surgery, West China Hospital, Chengdu, China.
authors.forename: Z
authors.initials: Z
authors.lastname: You
authors.affiliation: Biliary Surgery, West China Hospital, Chengdu, China.
authors.forename: L
authors.initials: L
authors.lastname: Bei
authors.affiliation: Biliary Surgery, West China Hospital, Chengdu, China.
authors.forename: L P
authors.initials: LP
authors.lastname: Cheng
authors.affiliation: Biliary Surgery, West China Hospital, Chengdu, China yurihobadehoya@126.com.
authors.forename: N S
authors.initials: NS
authors.lastname: Cheng
mesh_terms: D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018281:Cholangiocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D051546:Cyclooxygenase 2 / Q000096:biosynthesis* / Q000235:genetics; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D042582:Vascular Endothelial Growth Factor C / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D042582:Vascular Endothelial Growth Factor C; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human